Saxagliptin Triple Oral Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 257 participants.

Also called NCT01128153

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 257 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01128153
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Canada, India, South Korea, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01128153. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-08-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Saxagliptin Triple Oral Therapy
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01128153
Content hash
95e717e37f884db6ebe3200fc5d0fbc9d2ddb393950bb2c3ba29e950f51d10f2